Description: Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its cell therapy technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is also advancing various peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including its Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In addition, it develops a proprietary DNA expression technology, known as PolyStart, to improve the ability of the cellular immune system to recognize and destroy diseased cells. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Home Page: www.markertherapeutics.com
MRKR Technical Analysis
3200 Southwest Freeway
Houston,
TX
77027
United States
Phone:
713 400 6400
Officers
| Name | Title |
|---|---|
| Mr. Peter L. Hoang MBA | Pres, CEO & Director |
| Dr. Mythili Koneru M.D., Ph.D. | Chief Medical Officer |
| Dr. Juan F. Vera M.D. | Co-Founder, COO, Chief Scientific Officer & Director |
| Mr. Michael J. Loiacono | Chief Accounting Officer, Treasurer & Sec. |
| Ms. Elizabeth Donnelly | Director of Admin. |
| Mr. Edmund Cheung | VP of HR |
| Dr. Nadia Agopyan Ph.D. | Sr. VP of Regulatory Affairs |
| Dr. Robert Z. Florkiewicz Sr. | Sr. Director of Molecular Biology & Virology |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.1336 |
| Price-to-Sales TTM: | 3.5926 |
| IPO Date: | 2014-03-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 56 |